Acrivon Therapeutics Announces Positive Phase 2b ACR‑368 Endometrial Cancer Results, Expands EU Enrollment, Shares Initial ACR‑2316 Data and Unveils ACR‑6840 Development Candidate

Acrivon Therapeutics, Inc. (Nasdaq: ACRV), a clinical‑stage biotechnology firm, announced positive interim data from its Phase 2b registrational‑intent trial of ACR‑368 for endometrial cancer. The electronic data capture extract showed a 39% overall response rate (ORR) in OncoSignature‑positive subjects and 44% ORR in those with ≤2 prior therapies. In the high‑need serous subtype group, the confirmed ORR was 52% overall and 67% among biomarker‑positive patients. Based on these results, Acrivon has submitted a European Clinical Trial Application for Arm 3 of the study, which combines ACR‑368 with ultra‑low dose gemcitabine (ULDG) and plans to enroll up to 90 serous patients without requiring tumor biopsy. EU enrollment is expected to begin in Q1 2026 with full enrollment targeted by Q4 2026. In addition, the company reported initial clinical activity from the Phase 1 trial of ACR‑2316, a potential first‑in‑class WEE1/PKMYT1 inhibitor, in 33 patients. Two weekly oral regimens were established, and tumor shrinkage was observed in 9 of 20 evaluable subjects, including a confirmed partial response in endometrial cancer and unconfirmed responses in small cell lung cancer and squamous NSCLC. Acrivon also nominated ACR‑6840, an AP3‑derived oral CDK11 inhibitor, as its next development candidate, with an IND submission planned for Q4 2026. Furthermore, the company has submitted a Phase 3 confirmatory protocol to the FDA evaluating ACR‑368 with an anti‑PD‑1 therapy in frontline endometrial cancer, expecting global trial readiness by mid‑2026. Acrivon reported about $119 million in cash, cash equivalents and investments as of December 31, 2025, supporting operations into Q2 2027. #AcrivonTherapeutics #EndometrialCancer #ClinicalTrial #BiotechInnovation #SlimScan #GrowthStocks #CANSLIM